🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to health experts.

An International Health Concern

The sexually transmitted infection are on the rise worldwide, with estimates suggesting more than 82 million infections per year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the context of rising global incidence, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring found that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts believe that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in the same week. This medication, which is also used to treat UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This authorization represents a huge turning point in the therapy of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Results and Global Access

Based on data published in a major medical journal, zoliflodacin eradicated over nine in ten of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The research enrolled over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have expressed optimism. The availability of a single-dose, oral treatment of this kind is described as a "critical tool" for public health efforts. This is deemed vital to reduce the burden of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.